Asked by: John Lamont (Conservative - Berwickshire, Roxburgh and Selkirk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps is his Department is taking to ensure brain tumour patients have timely access to whole genome sequencing.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Genomic testing is delivered through the NHS Genomic Medicine Service via seven regional NHS Genomic Laboratory Hubs (NHS GLHs). Testing follows the National Genomic Test Directory, which includes whole genome sequencing (WGS) for neurological tumours, including primary brain cancers. NHS England has produced national sample handling guidance for WGS of solid tumours, including brain tumours, to maintain DNA quality and improve access to WGS by standardising the collection, processing, and transport of samples. Approaches to the handling of fresh tissue have also been reviewed to speed up processes. In 2025/26, NHS England is continuing its Cancer Genomics Improvement Programme to deliver quality improvement initiatives, education, local engagement, and the establishment of Cellular Pathology Genomic Centres to streamline cancer genomics pathways and accelerate genomic testing. These approaches are addressing variability and ensuring equitable regional access to WGS for brain tumour patients. NHS England monitors performance through Patient Level Contract Monitoring data and works with NHS GLHs to address variation and drive improvements.
Asked by: Lee Dillon (Liberal Democrat - Newbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what support he is providing to the Buckinghamshire, Oxfordshire and Berkshire Integrated Care Board to ensure that people are receiving timely treatment for brain cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department recognises that there are currently limited treatment options available for people who have been diagnosed with brain tumours, and the significant impact that rarer forms of cancer can have on patients, carers, and their families. The Government is invested in driving new lifesaving and life-improving research, supporting those diagnosed and living with brain tumours.
We have already invested £70 million in replacing outdated radiotherapy machines across the National Health Service with new cutting-edge technology that will speed up treatment for thousands of patients, and this includes a new machine to be situated in the Royal Berkshire NHS Foundation Trust.
Additionally, the Government supports Scott Arthur’s Private Members Bill on rare cancers which will make it easier for clinical trials into rare cancers, such as brain cancers, to take place across England by ensuring the patient population can be easily contacted by researchers. This will ensure that the NHS will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options and ultimately boost survival rates.
Early next year, the Government will publish a National Cancer Plan which will set out targeted actions to reduce lives lost to cancers and improve the experience of patients, including those with brain cancer.
Asked by: Richard Holden (Conservative - Basildon and Billericay)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what potential new treatments for glioblastoma have been trialled in the NHS.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care enables research via its research arm, the National Institute for Health and Care Research (NIHR), and is committed to furthering our investment and driving scientific advancements in research into the causes and treatment of brain tumours. Between 2018/19 and 2023/24, the NIHR directly invested £11.8 million via research programmes and training. UK Research and Innovation, funded by the Department for Science, Innovation and Technology, invested £46.8 million.
During the same period, the NIHR’s wider investments of approximately £37.5 million in research infrastructure and the research workforce have enabled the delivery of an additional 261 brain tumour research studies, allowing over 11,400 more people to participate in brain tumour research. NIHR infrastructure provides world-class research expertise, specialist facilities, a research delivery workforce, and support services to enable and deliver research across the National Health Service and wider health and care system.
For example, the CITADEL-123 trial, supported by the NIHR’s University College London Hospital (UCLH) Clinical Research Facility and the UCLH Biomedical Research Centre, is trialling the use of resection surgery followed by implantation of a medical device which delivers radioactive therapy in patients with recurrent glioblastoma. A separate trial of a drug derived from olive oil has shown promise in early studies for patients with glioblastoma. The NIHR Biomedical Research Centre at the Royal Marsden and the Institute of Cancer Research and Experimental Cancer Medicine Centre Network, which the NIHR jointly funds, support the work of the Drug Development Unit, which supported the study.
The Win-Glio trial, also supported by the NIHR’s UCLH Clinical Research Facility, is testing immunotherapy treatment using the drug ipilimumab prior to standard treatment in patients with glioblastoma.
The NIHR continues to welcome funding applications for research into any aspect of human health and care, including glioblastoma. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to the public and health and care services, value for money, and scientific quality.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what plans they have to ensure that more research and clinical trials are undertaken into the causes and treatment of brain cancer.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department delivers research via the National Institute for Health and Care Research (NIHR) and is committed to furthering our investment and driving scientific advancements in research into the causes and treatment of brain tumours. Between 2018/19 and 2023/24, the NIHR invested £11.8 million, and UK Research and Innovation invested £46.8 million in this area.
During the same period, the NIHR’s wider investments of approximately £37.5 million in research infrastructure and the research workforce have enabled the delivery of an additional 261 brain tumour research studies, allowing over 11,400 more people to participate in brain tumour research. NIHR infrastructure provides world-class research expertise, specialist facilities, a research delivery workforce, and support services to enable and deliver research across the National Health Service and wider health and care system.
In September 2024 the NIHR launched a package of support to deliver a step-change in brain cancer research by establishing a national NIHR Brain Tumour Research Consortium to bring together researchers from different disciplines to drive scientific advancements in how to prevent, detect, manage, and treat brain tumours. We will announce funding decisions this year, including a dedicated funding call for research into care, support, and rehabilitation for people living with brain tumours, as well as the Allied Health Professionals Brain Tumour Research Fellowship programme, a partnership with the Tessa Jowell Brain Cancer Mission.
These funding calls mark an innovative collaboration between charities, research funders, and the Government to listen and consult with the brain tumour community to increase and accelerate research into brain tumours. The NIHR continues to welcome funding applications for research into any aspect of human health and care, including brain tumours.
To improve clinical trial access for brain tumour patients, the 10-Year Health Plan outlines how the Department will fast-track clinical trial set-up time to 150 days by March 2026. We are building capacity to deliver clinical trials through 21 new Commercial Research Delivery Centres across the United Kingdom, and we also support the Rare Cancers Private Members Bill. Once implemented, this bill will make it easier for brain tumour patients to be recruited to clinical trials.
Additionally, the National Cancer Plan will include further details on how we will improve outcomes for cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, including access to genetic testing to support treatment.
Asked by: Luke Akehurst (Labour - North Durham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when people with brain cancer will have access to personalised vaccines as part of their NHS treatment.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
There are currently no personalised cancer vaccines with a marketing authorisation for use in the United Kingdom. All new, licensed medicines, including personalised cancer vaccines, are evaluated by the National Institute for Health and Care Excellence (NICE) which makes recommendations on whether they should be routinely funded by the National Health Service, based on an assessment of clinical and cost effectiveness. NICE aims wherever possible to issue recommendations on new medicines close to the point of licensing, and cancer medicines are eligible for funding from the Cancer Drugs Fund from the point of a positive draft NICE recommendation, bringing forward patient access by up to five months.
The measures that we announced in the Life Sciences Sector Plan will enhance NICE’s collaboration with the Medicines and Healthcare products Regulatory Agency and will support faster access to medicines for NHS patients in England.
Further, the NHS Cancer Vaccine Launch Pad (CVLP) is a platform set up to accelerate the development of cancer vaccines and speed up access to mRNA personalised cancer vaccine clinical trials for cancer patients. The CVLP has been instrumental in accelerating trial activity in cancer research, with CVLP sites driving faster activation and enrolment timelines. The platform is designed to be company- and clinical trial type-agnostic. Any company that wishes to deliver trials via the platform, including those developing vaccines for brain tumours, can contact the CVLP to explore how the platform can support their research.
Asked by: John Hayes (Conservative - South Holland and The Deepings)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many and what proportion of patients in (1) Lincolnshire and (2) England have waited for (a) 90 and (b) 150 days for brain tumour test results in each of the last three years.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England publishes waiting time data from referral to being informed of a cancer diagnosis or having it ruled out for brain and central nervous system. This is the 28-day Faster Diagnosis Standard. This includes the waiting time data for patients in Lincolnshire Integrated Care Board and in England.
This data is publicly available at the following link:
https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/
Asked by: Danny Chambers (Liberal Democrat - Winchester)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to (a) support, (b) rollout and (c) ensure equality of regional access to whole Genome Sequencing for primary brain cancer patients; and what plans he has to review (i) refrigeration issues, (ii) access and (iii) speed of processing.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Genomic testing is delivered through the NHS Genomic Medicine Service via seven regional NHS Genomic Laboratory Hubs (NHS GLHs). Testing follows the National Genomic Test Directory, which includes whole genome sequencing (WGS) for neurological tumours, including primary brain cancers, for both diagnostic and treatment purposes. NHS England has produced national sample handling guidance for WGS of solid tumours, including brain tumours, to standardise collection, processing, and transport. This supports collaboration between neurosurgeons, pathologists, and NHS GLHs to maintain DNA quality and improve access to WGS. Approaches to the handling of fresh tissue have been reviewed, including the use of tissue stabilisers, to reduce some of the barriers of having to acquire, freeze, and transport the frozen tissue, which will speed up processes. These measures aim to address variability and ensure equitable regional access to WGS for brain tumour patients. NHS England monitors performance through Patient Level Contract Monitoring data and works with NHS GLHs to address variation and drive improvements.
Asked by: Adam Jogee (Labour - Newcastle-under-Lyme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make a comparative assessment of the adequacy of funding for research and innovation for (a) less survivable cancers and (b) other cancer types.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in tackling cancer, which is why the Department invests £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). Cancer is one of the largest areas of spend at over £141.6 million in 2024/25, reflecting its high priority.
These investments are pivotal to informing efforts to improve cancer prevention, treatment, and outcomes. An example of this investment is the Imperial College London research on breath tests to detect less survivable cancers, with further information available at the following link:
https://imperialbrc.nihr.ac.uk/2023/06/05/imperial-led-uk-cancer-breath-tests-reach-final-stages/
Another example of Government investment was the launch of the NIHR’s national Brain Tumour Research Consortium in September 2024, which is bringing together researchers from a range of different disciplines and institutions with the aim of making scientific advances in how we prevent, detect, manage, and treat rare and less-survivable brain tumours in adults and children.
The NIHR continues to welcome funding applications for research into less common cancers and other cancer types. The forthcoming National Cancer Plan will include further details on how the National Health Service will improve diagnosis and outcomes for all cancer patients in England, including for less common cancers, and other cancer types.
Asked by: David Simmonds (Conservative - Ruislip, Northwood and Pinner)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much and what percentage of total research expenditure has been spent on research into (a) Giloma, (b) Glioblastoma, (c) Astrocytoma, (d) DIPG and (e) DMG brain tumour types in the last decade.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in tackling cancer, which is why the Department invests over £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). Cancer is one of NIHR’s largest areas of spend at over £133 million in 2023/24, reflecting its high priority.
Between 2018/19 and 2023/24, the NIHR directly invested £11.8 million in research projects focused on brain tumours. These investments are pivotal towards efforts to improve cancer prevention, treatment and outcomes. Data for 2024/25 is not yet available.
The following table shows the percentage of research expenditure invested on specific cancer subtypes for the period 2014/15 to 2024/25:
Type | Amount | % of total NIHR programme spend (£6.1 billion) |
Glioma | £3.1m | 0.052% |
Glioblastoma | £3.2m | 0.053% |
Astrocytoma | £0.4m | 0.007% |
DIPG | - | - |
DMG | - | - |
Total | £6.8m | 0.112% |
In addition, the NIHR’s wider investments in research infrastructure, for instance facilities, services, and the research workforce, are estimated to be £37.5 million, supporting the delivery of 261 brain tumour research studies and enabling over 11,400 people to participate in potentially life-changing brain tumour research in the National Health Service.
Working with stakeholders from across the research community, in September 2024 NIHR launched a package of support to stimulate high-quality research applications through:
i. establishing a national Brain Tumour Research Consortium to bring together researchers from different disciplines to drive scientific advancements in how to prevent, detect, manage and treat brain tumours;
ii. a dedicated funding call for research into wraparound care and rehabilitation for people living with brain tumours; and
iii. a partnership with the Tessa Jowell Brain Cancer Mission to fund the next generation of researchers through the Allied Health Professionals Brain Tumour Research Fellowship programme.
The NIHR funds research in response to proposals received from scientists rather than allocating funding to specific disease areas in advance. The level of research spend in a particular area is driven by factors including scientific potential and the number and scale of successful funding applications. NIHR continues to welcome funding applications for research into any aspect of human health and care, including all cancer types.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what action they have taken to incentivise investment and reduce barriers in brain cancer research for the pharmaceutical and life science sector in the areas of (1) transitional research, (2) early stage research, (3) advanced novel therapeutics, (4) optimisation of existing treatments, and (5) repurposing drug trials.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Government responsibility for delivering brain cancer research is shared between the Department for Health and Social Care, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation (UKRI). The Medical Research Council (MRC) funds fundamental discovery science through to the development and testing of new diagnostics, therapeutic interventions, and preventive measures whilst the NIHR funds applied health and care research that turns discoveries into new or improved treatments, diagnostics, medical technologies, or services.
To bridge the gap between early findings and clinical practice, the NIHR supports translational research focused on patient-centred research and healthcare. NIHR Biomedical Research Centres take leading-edge cancer research from the laboratory and rapidly translate it into clinical trials. The NIHR Innovation Observatory scans for new opportunities to identify emerging interventions or those with the potential for repurposing.
In September 2024, the NIHR announced a new approach to transform the outcomes for patients and their families who are living with brain tumours, ultimately reducing the lives lost to cancer. This will be done by maximising the United Kingdom’s clinical trials potential and working with the life sciences sector to make the UK a leading location for brain tumour research.
The UKRI offers a broad range of funding opportunities to support brain tumour research, including in partnership with industry. The MRC has actively engaged with brain tumour researchers to encourage applications The MRC has also identified the need for better disease models which informed a recent MRC-led funding opportunity to improve human in vitro models, and which resulted in two awards that will explore improving the use of human brain tumour tissue in research.
The Government is committed to furthering our investment and support for high-quality brain tumour research, ensuring that funding is used in the most meaningful and impactful way, and the NIHR continues to welcome further high-quality proposals from researchers to inform approaches to prevention, treatment, and care in relation to brain cancer.
The Department of Health and Social Care is committed to ensuring that all patients, including those with brain cancer, have access to cutting-edge clinical trials and innovative, lifesaving treatments. The forthcoming National Cancer Plan will include further details on how the National Health Service will improve diagnosis and outcomes for all cancer patients in England, including for those with brain cancer.
The Government also supports the Rare Cancers Private Members Bill. The bill will make it easier for clinical trials on brain cancer to take place in England, by ensuring the patient population can be more easily contacted by researchers.